Back to top
more

The Joint (JYNT)

(Delayed Data from NSDQ)

$15.93 USD

15.93
118,406

-0.49 (-2.98%)

Updated May 28, 2024 04:00 PM ET

After-Market: $15.96 +0.03 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for JYNT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

The Joint Corp. [JYNT]

Reports for Purchase

Showing records 101 - 120 ( 149 total )

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 101

05/12/2017

Company Report

Pages: 5

1Q results better than expected, minimal changes to model and reiterating BUY

Provider: Feltl & Company

Analyst: SMITH M

Price: 10.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 102

04/19/2017

Company Report

Pages: 6

NDRS with management confirms our thesis, reiterating BUY rating and $6 target

Provider: Feltl & Company

Analyst: SMITH M

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 103

03/10/2017

Company Report

Pages: 7

4Q revenue inline and bottom line beat, guidance below expectations, reiterating BUY

Provider: Feltl & Company

Analyst: SMITH M

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 104

01/30/2017

Company Report

Pages: 9

NDRS with CEO/CFO yield favorable views, we like this store for long-term growth

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 105

01/09/2017

Company Report

Pages: 6

Chicago sold/closed - $5mm line should bolster stock, burn higher than we model?

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 106

11/11/2016

Company Report

Pages: 8

Pleased with 3Q:16 and guidance, positive EBITDA coming sooner but cash looks tight

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 107

10/18/2016

Company Report

Pages: 7

Travels with management provides insight on EBITDA, cash, store profits, Chicago

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 108

08/12/2016

Company Report

Pages: 7

Losses diminishing, strong store economics versus liquidity management

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 109

07/22/2016

Company Report

Pages: 7

Pre-release generally favorable, much to learn yet but seeing reasons for optimism

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 110

07/01/2016

Company Report

Pages: 7

CEO departs; board focus-cash, store ops, franchises; reboot or tighter performance?

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 111

06/24/2016

Company Report

Pages: 7

CFO resignation, rating to BUY, near-term risk versus exceptional store economics

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 112

05/19/2016

Company Report

Pages: 10

Travels with management yield thoughts on store-level results, long-term outlook

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 113

05/13/2016

Company Report

Pages: 8

1Q met our revenue, beat our EBITDA, but forward EBITDA guided lower

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 114

05/11/2016

Company Report

Pages: 6

1Q preview: retail revenue ramp, quarterly EBITDA loss peaks near $(3.0mm)

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 115

03/17/2016

Company Report

Pages: 8

4Q slight miss, unit guidance lower than modeled, EBITDA starts improving soon

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 116

03/15/2016

Company Report

Pages: 6

4Q tomorrow, expect revenue ramp, EBITDA losses peaking 1Q and positive in 2017

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 117

03/15/2016

Company Report

Pages: 6

4Q tomorrow, expect revenue ramp, EBITDA losses peaking 1Q and positive in 2017

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 118

01/11/2016

Company Report

Pages: 4

We are dropping coverage of JYNT to focus our resources on other areas within the consumer sector

Provider: Roth Capital Partners, Inc.

Analyst: BRENNER A

Price: 10.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 119

01/04/2016

Daily Note

Pages: 6

2016 Top Ideas

Provider: Feltl & Company

Price: 25.00

Research Provided by a Third Party

Company: The Joint Corp.

Industry: Medical - HMOs

Record: 120

12/29/2015

Company Report

Pages: 8

Model update for offering, emphasis on development vs. acquisition, PT to $12.40

Provider: Feltl & Company

Analyst: RYSTROM B

Price: 25.00

Research Provided by a Third Party